Carcinoma: all 6,715 studies
Page 34 of 68. Open to participants first (1,140), then studies with results posted, then the rest; newest registration first within each.
- A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedNCT04635527Phase 1
- Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell CarcinomaActive, not recruitingNCT04632433Phase 2
- A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04627961Phase 2
- Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012
- Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic IrradiationCompletedNCT04626466
- Perioperative Management in Gynaecological Carcinoma SurgeryWithdrawnNCT04625530Phase 3
- Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
- Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)Status unknownNCT04619342Not applicable
- Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)Status unknownNCT04619329Not applicable
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
- A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like CarcinomaStatus unknownNCT04614818
- Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04611321Phase 1/2
- Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCCCompletedNCT04611165Phase 2
- Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.WithdrawnNCT04609800
- Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaStatus unknownNCT04609293
- Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)CompletedNCT04606940
- Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT04605185Phase 1
- A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial CarcinomaStatus unknownNCT04603846Phase 1
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnNCT04603365Phase 2
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Phase 1
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerWithdrawnNCT04602117Phase 1
- Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04602013Phase 2
- Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma PatientsStatus unknownNCT04601961Not applicable
- GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 TherapyCompletedNCT04601402Phase 1
- TACE Combined With Lenvatinib and Sintilimab for Advanced HCCCompletedNCT04599790Phase 2
- TACE Combined With Sorafenib and Tislelizumab for Advanced HCCCompletedNCT04599777Phase 2
- TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCStatus unknownNCT04597970Phase 2
- TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTerminatedNCT04596033Phase 1
- NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing SurgeryTerminatedNCT04588038Phase 1
- Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
- Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART StudyWithdrawnNCT04585932Phase 2
- The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin TumorsStatus unknownNCT04583605
- Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
- Comparison of Criteria for Liver Transplantation in Hepatocellular CarcinomaCompletedNCT04576572
- Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell CarcinomasStatus unknownNCT04570683Early Phase 1
- Prevention of Hand-foot Skin ReactionCompletedNCT04568330Not applicable
- Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Phase 2
- Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
- Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver TransplantationStatus unknownNCT04564313Phase 1
- The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled TrialCompletedNCT04562428Phase 4
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT04560894Phase 2/3
- TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)Status unknownNCT04560751
- TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
- Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
- Cytokine Change in Hepatocellular Carcinoma Treated by Thermal AblationCompletedNCT04555265Not applicable
- Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation TherapyStatus unknownNCT04554680Phase 2
- Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic CarcinomaStatus unknownNCT04554524Phase 4
- Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular CarcinomaCompletedNCT04553458
- Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After TreatmentStatus unknownNCT04552236
- Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingNCT04551495Phase 2
- Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast CancerTerminatedNCT04549584
- Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCompletedNCT04548440Phase 2
- Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
- Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
- HepATocellular Cancer Hcv Therapy StudyWithdrawnNCT04546802Phase 3
- Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine LearningStatus unknownNCT04543266
- Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsTerminatedNCT04541225Phase 1
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedNCT04540705Phase 1
- Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of NasopharynxStatus unknownNCT04538547Not applicable
- A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILsStatus unknownNCT04538313Phase 1/2
- Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaCompletedNCT04535687Phase 2
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take CisplatinActive, not recruitingNCT04533750Phase 1
- A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04533490Phase 2
- A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell CarcinomaStatus unknownNCT04533321Phase 2
- Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT04526080Phase 2
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
- Phonosurgical Augmentation After Laser Resection of Early Glottic CarcinomaCompletedNCT04525066Phase 2
- Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular CarcinomaStatus unknownNCT04523467Not applicable
- Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
- Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingNCT04520711Phase 1
- TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCCCompletedNCT04518852Phase 2
- Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical TrialStatus unknownNCT04518774Early Phase 1
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
- Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04517214Phase 2
- Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCCStatus unknownNCT04514822Not applicable
- The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.Status unknownNCT04513119
- Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line TreatmentCompletedNCT04511455Phase 2
- Effects of Anesthetic Methods on Hepatic Cancer Cell Function in VitroCompletedNCT04510935Not applicable
- Optical Coherence Tomography Guided C&DWithdrawnNCT04510727Not applicable
- Spanish Real-World Evidence CabozantinibCompletedNCT04510688
- SmartQuit Program for Smoking CessationCompletedNCT04510077Not applicable
- Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction ChemotherapyStatus unknownNCT04508829Phase 2
- Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyCompletedNCT04508816Phase 2
- Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
- GPC3-CAR-T Cells for the Hepatocellular CarcinomaSuspendedNCT04506983Phase 1
- Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC RecurrenceStatus unknownNCT04506398
- Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04506138Phase 1/2
- Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
- Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04503902Phase 1/2
- Anesthesia and Cancer Study: Renal Cell CarcinomaActive, not recruitingNCT04503148Not applicable
- A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal CancerWithdrawnNCT04499352Phase 2
- Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle BiopsyCompletedNCT04498611Not applicable
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCCCompletedNCT04496089Phase 1
- Role of CEUS as a Secondary Diagnostic ModalityStatus unknownNCT04494022Not applicable
- TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2
- Combining Risk Factors and Faecal Immunochemical Testing in Colorectal Cancer Screening: a Randomized Controlled TrialCompletedNCT04490551Not applicable
- Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown PrimariesCompletedNCT04489212Not applicable
- B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 1
- Study of TACE Combined With Camrelizumab in the Treatment of HCC PatientsActive, not recruitingNCT04483284Phase 2